520
Participants
Start Date
February 1, 2022
Primary Completion Date
April 11, 2023
Study Completion Date
March 18, 2024
Switch to B/F/TAF
This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide
Continue current regimen
Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu
Kenyatta National Hospital, Nairobi
Collaborators (1)
Gilead Sciences
INDUSTRY
University of Nairobi
OTHER